Prior characterization of histologic features that are associated with tumor response to IL-2, showed that in patients with conventional renal cell carcinoma 21% (30/146 patients) respond to IL-2, whereas in non-clear cell subtypes, only 6% (1/17 patients) respond to IL-2 [12]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.